What development phase is VERATRUM VIRIDE ROOT in?

VERATRUM VIRIDE ROOT is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

VERATRUM VIRIDE ROOT

FDA-approved approved Quality 0/100

Veratrum viride root is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant competitive advantage until then. The primary risk is the potential for increased competition following the 2028 patent expiry.

At a glance

Generic name	VERATRUM VIRIDE ROOT
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VERATRUM VIRIDE ROOT CI brief — competitive landscape report
VERATRUM VIRIDE ROOT updates RSS · CI watch RSS